BL-MOL-AR Project, Preliminary Results about Liquid Biopsy: Molecular Approach Experience and Research Activity in Oncological Settings

Abstract

Background Liquid biopsy is mainly used to identify tumor cells in pulmonary neoplasms. It is more often used in research than in clinical practice. The BL-MOL-AR study aims to investigate the efficacy of next-generation sequencing (NGS) and clinical interpretation of the circulating free DNA (cfDNA) levels. This study reports the preliminary results from the first samples analyzed from patients affected by various neoplasms: lung, intestinal, mammary, gastric, biliary, and cutaneous.
Methods The Biopsia Liquida-Molecolare-Arezzo study aims to enroll cancer patients affected by various malignancies, including pulmonary, intestinal, advanced urothelial, biliary, breast, cutaneous, and gastric malignancies. Thirty-nine patients were included in this preliminary report.
At time zero, a liquid biopsy is executed, and two types of NGS panels are performed, comprising 17 genes in panel 1, which is already used in the routine tissue setting, and 52 genes in panel 2. From the 7th month after enrollment, 10 sequential liquid biopsies are performed up to the 17th month. The variant allele frequency (%) and cfDNA levels (ng/mL) are measured in every plasmatic sample.
Results The NGS results obtained by different panels are similar even though the number of mutations is more concordant for lung pathologies. There are no significant differences in the actionability levels of the identified variants. Most of the molecular profiles of liquid biopsies reflect tissue data.
Conclusions Preliminary data from this study confirm the need to clarify the limitations and potential of liquid biopsy beyond the lung setting. Overall, parameters related to cfDNA levels and variant allele frequency could provide important indications for prognosis and disease monitoring.

Keywords

liquid biopsy / cfDNA / NGS

References

[1] Malapelle U, Pisapia P, Addeo A. et al. Liquid biopsy from research to clinical practice: focus on non-small cell lung cancer. Expert Rev Mol Diagn 2021;21(11):1165-1178

[2] The global challenge of cancer. Nat Cancer 2020;1(01):1-2

[3] Gao W, Huang T, Yuan H. et al. Highly sensitive detection and mutational analysis of lung cancer circulating tumor cells using integrated combined immunomagnetic beads with a droplet digital PCR chip. Talanta 2018;185:229-236

[4] Balaji SA, Shanmugam A, Chougule A. et al. Analysis of solid tumor mutation profiles in liquid biopsy. Cancer Med 2018;7(11):5439-5447

[5] Schwaederle M, Husain H, Fanta PT. et al. Detection rate of actionable mutations in diverse cancers using a biopsy-free (blood) circulating tumor cell DNA assay. Oncotarget 2016;7(09):9707-9717

[6] Mattox AK, Bettegowda C, Zhou S, Papadopoulos N, Kinzler KW, Vogelstein B. Applications of liquid biopsies for cancer. Sci Transl Med 2019;11(507)eaay1984

[7] Thomsen CB, Hansen TF, Andersen RF, Lindebjerg J, Jensen LH, Jakobsen A. Monitoring the effect of first line treatment in RAS/RAF mutated metastatic colorectal cancer by serial analysis of tumor specific DNA in plasma. J Exp Clin Cancer Res 2018;37(01):55

[8] Malczewska A, Oberg K, Bodei L. et al. NETest liquid biopsy is diagnostic of lung neuroendocrine tumors and identifies progressive disease. Neuroendocrinology 2019;108(03):219-231

[9] Endzeliņš E, Berger A, Melne V. et al. Detection of circulating miRNAs: comparative analysis of extracellular vesicle-incorporated miRNAs and cell-free miRNAs in whole plasma of prostate cancer patients. BMC Cancer 2017;17(01):730

[10] Malentacchi F, Vinci S, Melina AD. et al. Urinary carbonic anhydrase IX splicing messenger RNA variants in urogenital cancers. Urol Oncol 2016;34(07)292.e9-292.e16

[11] Zedan AH, Hansen TF, Assenholt J, Madsen JS, Osther PJS. Circulating miRNAs in localized/locally advanced prostate cancer patients after radical prostatectomy and radiotherapy. Prostate 2019;79(04):425-432

[12] Okajima W, Komatsu S, Ichikawa D. et al. Circulating microRNA profiles in plasma: identification of miR-224 as a novel diagnostic biomarker in hepatocellular carcinoma independent of hepatic function. Oncotarget 2016;7(33):53820-53836

[13] Sestini S, Boeri M, Marchiano A. et al. Circulating microRNA signature as liquid-biopsy to monitor lung cancer in low-dose computed tomography screening. Oncotarget 2015;6(32):32868-32877

[14] Keup C, Mach P, Aktas B. et al. RNA profiles of circulating tumor cells and extracellular vesicles for therapy stratification of metastatic breast cancer patients. Clin Chem 2018;64(07):1054-1062

[15] Zhou B, Xu K, Zheng X. et al. Application of exosomes as liquid biopsy in clinical diagnosis. Signal Transduct Target Ther 2020;5(01):144

[16] Ilié M, Hofman P. Pros: can tissue biopsy be replaced by liquid biopsy?. Transl Lung Cancer Res 2016;5(04):420-423

[17] Martins I, Ribeiro IP, Jorge J. et al. Liquid biopsies: applications for cancer diagnosis and monitoring. Genes (Basel) 2021;12(03):349

[18] Pinzani P, D'Argenio V, Del Re M. et al. Updates on liquid biopsy: current trends and future perspectives for clinical application in solid tumors. Clin Chem Lab Med 2021;59(07):1181-1200

[19] Pascual J, Attard G, Bidard FC. et al. ESMO recommendations on the use of circulating tumour DNA assays for patients with cancer: a report from the ESMO Precision Medicine Working Group. Ann Oncol 2022;33(08):750-768

[20] Ungerer V, Bronkhorst AJ, Holdenrieder S. Preanalytical variables that affect the outcome of cell-free DNA measurements. Crit Rev Clin Lab Sci 2020;57(07):484-507

[21] AIOM. Raccomandazioni 2020 per l'esecuzione di Test Molecolari su Biopsia Liquida in Oncologia. Accessed July 2, 2023 at: https://www.aiom.it/wp-content/uploads/2020/07/2020_Raccomandazioni_Biopsia_Liquida.pdf

[22] Sorber L, Zwaenepoel K, Deschoolmeester V. et al. A comparison of cell-free DNA isolation kits: isolation and quantification of cell-free DNA in plasma. J Mol Diagn 2017;19(01):162-168

[23] Thierry AR, El Messaoudi S, Gahan PB, Anker P, Stroun M. Origins, structures, and functions of circulating DNA in oncology. Cancer Metastasis Rev 2016;35(03):347-376

[24] Hench IB, Hench J, Tolnay M. Liquid biopsy in clinical management of breast, lung, and colorectal cancer. Front Med (Lausanne) 2018;5:9

[25] BIO-RAD. Rare mutation detection. Accessed July 2, 2023 at: https://www.bio-rad.com/webroot/web/pdf/lsr/literature/Bulletin_6628.pdf

[26] van Ginkel JH, Huibers MMH, van Es RJJ, de Bree R, Willems SM. Droplet digital PCR for detection and quantification of circulating tumor DNA in plasma of head and neck cancer patients. BMC Cancer 2017;17(01):428

[27] Richards S, Aziz N, Bale S. et al. ACMG Laboratory Quality Assurance Committee. Standards and guidelines for the interpretation of sequence variants: a joint consensus recommendation of the American College of Medical Genetics and Genomics and the Association for Molecular Pathology. Genet Med 2015;17(05):405-424

[28] Cainap C, Balacescu O, Cainap SS, Pop LA. Next generation sequencing technology in lung cancer diagnosis. Biology (Basel) 2021;10(09):864

[29] Mateo J, Chakravarty D, Dienstmann R. et al. A framework to rank genomic alterations as targets for cancer precision medicine: the ESMO Scale for Clinical Actionability of molecular Targets (ESCAT). Ann Oncol 2018;29(09):1895-1902

[30] Durães C, Gomes CP, Costa JL, Quagliata L. Demystifying the discussion of sequencing panel size in oncology genetic testing. EMJ 2022;7(02):68-77

[31] Jung A, Kirchner T. Liquid biopsy in tumor genetic diagnosis. Dtsch Arztebl Int 2018;115(10):169-174

RIGHTS & PERMISSIONS

2023 Global Medical Genetics